NeuroscienceAlzheimer s & DementiaPeer-reviewed
FDA-approved carbonic anhydrase inhibitors reduce Amyloid beta pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness
Elisa Canepa, Rebecca Maria Parodi‐Rullán, Rafael Vázquez‐Torres…·Silvia Fossati
This study tests FDA-approved carbonic anhydrase inhibitors in a transgenic AD model, finding they reduce amyloid beta pathology and improve cognition by enhancing cerebrovascular health and glial function.
50 citationstop 1%